Venclexta Plus Vidaza Improves Survival for AML Patients, AbbVie Reports
News
First-line treatment with a combination of Venclexta (venetoclax) and Vidaza (azacitidine) significantly extended survival in people with acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, as compared with Vidaza alone, AbbVie ... Read more